Ptc THERAPEUTICS, Inc. (PTCT) intrinsic value & 10-year financials
Ptc THERAPEUTICS, Inc. (PTCT) has a Graham intrinsic value of $258.42 per share. At $59.24 on Oct 17, 2026, the stock trades 77% below that value. Over the last 10 fiscal years revenue grew 40.2% a year to $1.7B, with an average return on invested capital of -53.1%.
- Graham intrinsic value
- $258.42
- Share price (Oct 17, 2026)
- $59.24
- Price vs Graham value
- 77% below
- Market cap
- $5.2B
- Revenue (FY2025)
- $1.7B
- Revenue growth (10-yr CAGR)
- 40.2%
- ROIC (10-yr avg)
- -53.1%
- Free cash flow (FY2025)
- $702.3M
PTCT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.7B | $682.6M | $7.78 | $702.3M | 50.1% | -73.6% |
| FY2024 | $806.8M | -$363.3M | -$4.73 | -$114.2M | -37.5% | 24.1% |
| FY2023 | $937.8M | -$626.6M | -$8.37 | -$186.9M | -46.9% | 83.4% |
| FY2022 | $698.8M | -$559.0M | -$7.79 | -$388.7M | -64.0% | -212.2% |
| FY2021 | $538.6M | -$523.9M | -$7.43 | -$279.5M | -69.5% | -73.3% |
| FY2020 | $380.8M | -$438.2M | -$6.64 | -$211.9M | -113.4% | -65.7% |
| FY2019 | $307.0M | -$251.6M | -$4.27 | -$112.4M | -78.6% | -50.1% |
| FY2018 | $264.7M | -$128.1M | — | -$34.7M | -43.7% | -44.2% |
| FY2017 | $194.4M | -$79.0M | — | -$13.2M | -33.1% | -36.8% |
| FY2016 | $82.7M | -$142.1M | — | -$105.3M | -159.7% | -82.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PTC THERAPEUTICS, INC. is a consistent compounder, expanding top-line revenue at 40.2% annually over the past decade.
PTC THERAPEUTICS, INC. has historically struggled to out-earn its cost of capital, averaging just -32.1% ROIC.
PTC THERAPEUTICS, INC. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, PTC THERAPEUTICS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $258.42 per share.